EOLS - Evolus, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
32.94
+1.00 (+3.13%)
At close: 4:00PM EDT

32.94 0.00 (0.00%)
After hours: 4:43PM EDT

Stock chart is not supported by your current browser
Previous Close31.94
Open32.00
Bid28.34 x 800
Ask32.80 x 1000
Day's Range30.24 - 33.10
52 Week Range6.75 - 39.50
Volume282,230
Avg. Volume421,090
Market Cap778.715M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.50
Trade prices are not sourced from all markets
  • GlobeNewswire8 hours ago

    Clinical Overview of PrabotulinumtoxinA for the Investigational Treatment of Frown Lines to Be Featured During Summer Cosmetic Bootcamp 2018

    Evolus, Inc. (EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the presentation of a comprehensive overview of the clinical program for its neuromodulator product candidate, DWP-450 (prabotulinumtoxinA), at the Summer Cosmetic Bootcamp taking place June 21-24, 2018 in Aspen, CO. The oral presentation “Toxin Update -- What We Have Now and What is Coming” will be delivered today during the Neurotoxin University module by Kenneth Beer, M.D., co-founder of the Cosmetic Bootcamp and voluntary Assistant Professor at the University of Miami. Dr. Beer will present top-line results of the Company’s three Phase III studies, all of which met their respective primary endpoints. This presentation expands on data presented at the American Academy of Dermatology (AAD) annual meeting in February 2018.

  • GlobeNewswire4 days ago

    Evolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer

    Evolus, Inc. (EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the expansion of its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juvederm Voluma®, which has been recognized as not only one of the largest launches in the medical aesthetics category, but also the most successful, as measured by year one sales.

  • GlobeNewswire8 days ago

    Evolus to Participate in Two Upcoming Investor Conferences

    IRVINE, Calif., June 14, 2018-- Evolus, Inc., a premiere aesthetics company, announced today that members of management will be participating in two upcoming investor conferences in New York, NY.. An audio ...

  • Why Nabors Industries, PolarityTE, and Evolus Slumped Today
    Motley Fool14 days ago

    Why Nabors Industries, PolarityTE, and Evolus Slumped Today

    Find out which of these stocks got criticism from a famous short-seller.

  • GlobeNewswire18 days ago

    Evolus to Present at the Jefferies 2018 Global Healthcare Conference

    IRVINE, Calif., June 04, 2018-- Evolus, Inc., a premiere aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, announced today that Lauren Silvernail, ...

  • GlobeNewswire24 days ago

    Evolus Appoints Veteran Healthcare Executive Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development

    Evolus, Inc. (EOLS) (“Evolus” or the “Company”), a premiere aesthetics company, today announced the appointment of Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development. Mrs. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance Therapeutics, Mrs. Silvernail was Chief Financial Officer and Vice President, Corporate Development at ISTA Pharmaceuticals Inc. working to grow the business from development stage through commercialization and into profitability until its acquisition by Bausch + Lomb.

  • Bloomberg29 days ago

    Rival to Botox Roars Back With 123% Rally Despite FDA Delay

    Evolus Inc. is reaching new highs, shrugging off a delay of potential approval of its Botox-rivaling wrinkle treatment. Why so much optimism when a Food and Drug Administration regulatory decision on the company’s key product, DWP-450, was pushed back from a hoped-for summer verdict to spring 2019? Some of the enthusiasm may stem from the company’s new Chief Executive Officer, David Moatazedi.

  • Reuterslast month

    Evolus investors frown as FDA declines to approve Botox rival

    U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines sending its shares down as much as 35 percent. The deficiencies that were communicated by the U.S. Food and Drug Administration in a so-called complete response letter were "manageable", according to CEO Moatazedi, who joined the company earlier this month after serving as U.S. head of Allergan's medical aesthetics business.

  • Business Wirelast month

    INVESTOR ALERT: Investigation on Behalf of Evolus Investors Announced by Holzer & Holzer

    Holzer & Holzer, LLC is investigating whether Evolus, Inc. complied with the federal securities laws. On May 16, 2018, Evolus announced that the FDA sent a Complete Response Letter related to the Company’s Biologics License Application for DWP-450, a developmental treatment of frown lines.

  • Why Evolus, Inc. Is Crashing Today
    Motley Foollast month

    Why Evolus, Inc. Is Crashing Today

    Shares swoon after the FDA gives the thumbs down to its lead compound. Here's what investors need to know.

  • Benzingalast month

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Biolinerx Ltd/S ADR (NASDAQ: BLRX ) stock was trading ...

  • GlobeNewswirelast month

    Evolus Announces Progress with DWP-450 Regulatory Submissions

    Evolus, Inc. (EOLS) (“Evolus”), a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for DWP-450 (prabotulinumtoxinA) to the U.S. Food and Drug Administration (“FDA”). The FDA issued an Establishment Inspection Report (“EIR”) to Daewoong Pharmaceutical Co. Ltd. (“Daewoong”) confirming the favorable completion of its pre-approval inspection of Daewoong’s manufacturing facility in South Korea which was purpose built for production of DWP-450.

  • GlobeNewswirelast month

    Evolus to Provide Regulatory Update on Wednesday, May 16, 2018

    IRVINE, Calif., May 16, 2018-- Evolus, Inc., a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, announced today that the Company ...

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 14) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. (NYSE: ...

  • GlobeNewswirelast month

    Evolus Reports First Quarter 2018 Financial Results

    IRVINE, Calif., May 10, 2018-- Evolus, Inc., a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today reported financial results ...

  • GlobeNewswire2 months ago

    Evolus Appoints Allergan Aesthetics Head as President and Chief Executive Officer

    IRVINE, Calif., May 07, 2018 (GLOBE NEWSWIRE) --  Evolus, Inc. (EOLS) (“Evolus” or the “Company”), a lifestyle aesthetics company, announced that its board of directors has named David Moatazedi as President and Chief Executive Officer. Mr. Moatazedi has nearly twenty years of commercial and executive experience building multiple market leading brands.  David also led several acquisitions for Allergan, including LifeCell™ for $2.9B and ZELTIQ® Aesthetics for $2.5B.

  • GlobeNewswire2 months ago

    Evolus to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

    IRVINE, Calif., May 03, 2018-- Evolus, Inc., a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced that Murthy Simhambhatla, ...

  • GlobeNewswire2 months ago

    Evolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS’ The Aesthetic Meeting

    IRVINE, Calif., April 23, 2018-- Evolus, Inc., a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced it will present ...

  • GlobeNewswire3 months ago

    Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint

    IRVINE, Calif., April 05, 2018-- Evolus, Inc., a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced the presentation ...

  • GlobeNewswire3 months ago

    Evolus Reports Fourth Quarter and Full Year 2017 Financial Results

    IRVINE, Calif., March 29, 2018-- Evolus, Inc., a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today reported financial results ...

  • Who Really Owns Evolus Inc (NASDAQ:EOLS)?
    Simply Wall St.4 months ago

    Who Really Owns Evolus Inc (NASDAQ:EOLS)?

    Today, I will be analyzing Evolus Inc’s (NASDAQ:EOLS) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure has been found to have an impact on shareholderRead More...

  • PR Newswire4 months ago

    Evolus Announces Presentation of Phase III European - Canadian Comparative Data

    IRVINE, Calif. , Feb. 17, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) today announced the presentation of data from the Phase III comparative clinical trial of its investigational prabotulinumtoxinA ...

  • PR Newswire4 months ago

    Evolus Announces Presentation of Phase III Comparative Data of PrabotulinumtoxinA and OnabotulinumtoxinA

    Trial Results to be Presented at American Academy of Dermatology Meeting IRVINE, Calif. , Feb. 16, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) today announced the presentation of data from the Phase ...

  • PR Newswire4 months ago

    Evolus, Inc. Announces Closing of Initial Public Offering of Common Stock

    IRVINE, Calif. , Feb. 12, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) ("Evolus"), a medical aesthetics company focused on providing physicians and their patients with expanded choices in ...